Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

CNS 2

Conditions

Neuroblastoma 2Pheochromocytoma 1Ganglioneuroblastoma 1

Interventions

Cyclophosphamide 28Temozolomide 25Irinotecan 21dinutuximab 20Topotecan 15Magnetic Resonance Spectroscopy 13Specimen Handling 12Biopsy 12naxitamab 11Granulocyte-Macrophage Colony-Stimulating Factor 113-Iodobenzylguanidine 11Vincristine 10Etoposide 10sargramostim 9Melphalan 9Isotretinoin 9fludarabine 8X-Rays 8Colony-Stimulating Factors 8Carboplatin 8etoposide phosphate 7Phantoms, Imaging 7Doxorubicin 7fludarabine phosphate 6Stem Cell Transplantation 6Nuclear Medicine Department, Hospital 6Eflornithine 6Thiotepa 5Granulocyte Colony-Stimulating Factor 5Filgrastim 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neuroblastoma × 3-fluorobenzylguanidine × 1 year × Clear all
NCT04724369 2026-04-03

Open-Label Study of 18F-mFBG for Imaging Neuroblastoma

Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)

Phase 3 Active not recruiting
43 enrolled
CNS

Neuroblastoma

NCT06852807 2025-08-08

18F-mFBG PET Imaging in the Evaluation of Neuroblastoma

First Affiliated Hospital of Zhejiang University

Recruiting
200 enrolled
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡